Evidence brief -Week 12

Brazil develops and rolls out single-dose dengue vaccine This article signals a major advance toward operationally feasible dengue vaccination, especially in high-burden, access constrained settings, and may preview broader regional uptake of single-dose strategies. Brazil has begun deploying Butantan-Dengue Vaccine, the world’s first single-dose tetravalent live-attenuated dengue vaccine, initially targeting about 1.1 million primary health-care workers nationwide. Phase 3 data from over 16,000 Brazilian participants showed 2 year efficacy of 79.6% overall against virologically confirmed dengue, with efficacy of 73.6% in seronegative and 89.2% in seropositive individuals, and robust protection against DENV 1 and DENV 2. A subsequent 3.7 year follow-up trial in the same cohort confirmed sustained efficacy of 67.3% against DENV 1/2. Regulatory approval was granted for individuals 12–59 years, and the vaccine will be supplied free of charge through the national health system. Large-scale production, including a partnership with WuXi Vaccines, aims for 60 million doses over two years,...